Global Intravenous Iron Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Intravenous Iron Drugs Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Iron is an essential element as it plays an important role in many vital biological processes such as the synthesis of heme which forms the basis of hemoglobin (Hb) the oxygen-carrying protein of the blood, the formation of myoglobin, energy metabolism, neurotransmitter production, the formation of collagen and immune system function. Lack of iron is one of the principal causes of anemia in the general population. It is not surprising that iron deficiency anemia (IDA) is associated with increased morbidity and mortality.
Intravenous Iron Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Intravenous Iron Drugs market is projected to reach US$ 1977.2 million in 2034, increasing from US$ 1449.2 million in 2022, with the CAGR of 4.1% during the period of 2024 to 2034. Demand from Nephrology and Gynecology & Obstetrics are the major drivers for the industry.
Treatment with intravenous iron is clearly superior to oral iron and presents several advantages such as faster and higher increase in Hb levels and replenishment of body iron stores. For these reasons, modern formulations of IV iron have emerged as safe and effective alternatives for IDA management.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Intravenous Iron Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Allergan
AMAG Pharmaceuticals
Daiichi Sankyo
Galenica
Pharmacosmos
Nippon Shinyaku
NOXXON Pharma
Rockwell Medical
Sanofi
Wanbang Biopharmaceutical
Segment by Type
Ferric Gluconate
Ferric Carboxymaltose
Iron Sucrose
Iron Dextran
Nephrology
Gynecology & Obstetrics
Gastroenterology
Oncology
Cardiology
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Intravenous Iron Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Intravenous Iron Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Intravenous Iron Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Intravenous Iron Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Intravenous Iron Drugs introduction, etc. Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Intravenous Iron Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Intravenous Iron Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Intravenous Iron Drugs market is projected to reach US$ 1977.2 million in 2034, increasing from US$ 1449.2 million in 2022, with the CAGR of 4.1% during the period of 2024 to 2034. Demand from Nephrology and Gynecology & Obstetrics are the major drivers for the industry.
Treatment with intravenous iron is clearly superior to oral iron and presents several advantages such as faster and higher increase in Hb levels and replenishment of body iron stores. For these reasons, modern formulations of IV iron have emerged as safe and effective alternatives for IDA management.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Intravenous Iron Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Allergan
AMAG Pharmaceuticals
Daiichi Sankyo
Galenica
Pharmacosmos
Nippon Shinyaku
NOXXON Pharma
Rockwell Medical
Sanofi
Wanbang Biopharmaceutical
Segment by Type
Ferric Gluconate
Ferric Carboxymaltose
Iron Sucrose
Iron Dextran
Segment by Application
Nephrology
Gynecology & Obstetrics
Gastroenterology
Oncology
Cardiology
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Intravenous Iron Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Intravenous Iron Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Intravenous Iron Drugs industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Intravenous Iron Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Intravenous Iron Drugs introduction, etc. Intravenous Iron Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Intravenous Iron Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.